Followers | 1078 |
Posts | 80297 |
Boards Moderated | 7 |
Alias Born | 03/10/2009 |
Tuesday, May 04, 2021 7:48:01 AM
Our initial focus is improving patients’ quality of life following major surgery by 1) accelerating postoperative return of gastrointestinal (GI) function to shorten their length of stay in the hospital and 2) prevention of post-surgical adhesions to reduce need for additional surgeries.
Additionally, we plan to pursue follow-on indications to address a myriad of health conditions and complications associated with chronic disruption of the intestinal mucosal barrier.
Our most advanced candidate, LB1143, is a Phase 3-ready oral protease inhibitor drug with the potential ability to protect intestinal integrity during and after surgery, representing a pipeline within a drug given the wide array of health complications that intestinal enzyme damage can cause.
https://www.palisadebio.com/pipeline/default.aspx
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent PALI News
- Palisade Bio Enters into Strategic Collaboration with Strand Life Sciences to Advance Precision Medicine Approach • GlobeNewswire Inc. • 04/23/2024 12:30:00 PM
- Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool • GlobeNewswire Inc. • 04/16/2024 12:30:00 PM
- Palisade Bio to Participate in the Virtual Investor Lunch Break Event • GlobeNewswire Inc. • 04/11/2024 01:15:00 PM
- Palisade Bio Presents Development Overview of PALI-2108 at the IBD Innovate: Product Development for Crohn’s & Colitis™ • GlobeNewswire Inc. • 04/10/2024 12:15:00 PM
- Palisade Bio Announces 1-for-15 Reverse Stock Split • GlobeNewswire Inc. • 04/03/2024 09:30:00 PM
- Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/27/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:35:16 PM
- Palisade Bio to Present at Digestive Disease Week (DDW) 2024 • GlobeNewswire Inc. • 02/15/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:54:03 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:10:04 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:38:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/13/2024 08:08:36 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/13/2024 07:51:09 PM
- Palisade Bio Provides Corporate Update and Reiterates Guidance • GlobeNewswire Inc. • 02/13/2024 01:35:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:03:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:38:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/08/2024 09:37:40 PM
- Correction Notice of Palisade Bio’s Press Release Announcing the Appointment of Clinical Advisory Board Members • GlobeNewswire Inc. • 02/08/2024 07:40:00 PM
- Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders • GlobeNewswire Inc. • 02/08/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/07/2024 01:30:10 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/06/2024 10:01:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 02/06/2024 10:00:32 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM